ZGNX - Zogenix, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
52.21
-0.45 (-0.85%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close52.66
Open52.62
Bid44.19 x 800
Ask0.00 x 1000
Day's Range51.63 - 52.93
52 Week Range33.43 - 62.75
Volume386,023
Avg. Volume457,856
Market Cap2.204B
Beta (3Y Monthly)1.98
PE Ratio (TTM)N/A
EPS (TTM)-3.28
Earnings DateNov 6, 2017 - Nov 10, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est71.27
Trade prices are not sourced from all markets
  • GlobeNewswire20 hours ago

    Zogenix to Present at Two Investor Conferences in April

    EMERYVILLE, Calif., March 25, 2019 -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that members of.

  • Sage Stock Pops on FDA Approval for Postpartum Depression Drug
    InvestorPlace6 days ago

    Sage Stock Pops on FDA Approval for Postpartum Depression Drug

    Sage Therapeutics (NYSE:SAGE) is popped yesterday on FDA approval of its postpartum depression drug -- the first of its kind. So far, SAGE stock is up 3%, but this on the back of a more than 70% run up year-to-date in anticipation of the news.Source: Shutterstock Postpartum depression is a sometimes life-threatening condition that can happen before or after a woman gives birth to a child. In serious cases, she may harm herself or her child as a result. It is estimated that as many as one in nine women who have recently given birth suffer from postpartum depression, but it is a little talked about condition, so up to half of cases go unreported. But now there is a specific treatment. Zulresso was approved as an IV treatment to be administered in a certified healthcare facility over 2.5 days. With no other drug on the market to treat postpartum depression, Sage has no competition to worry about. And with a market cap of $7.8 billion -- lower than the addressable market potential for this treatment -- biotech investors cannot afford to ignore SAGE stock. Efficacy of ZulressoIn two clinical studies where participants received Zulresso or placebo, those who were treated showed an improvement of depressive symptoms compared to the placebo group.InvestorPlace - Stock Market News, Stock Advice & Trading TipsSage Therapeutics recently raised $500 million through a SAGE stock offering on February 25. This cash infusion will give the company the capital it needs to roll out Zulresso following its approval. Sage Is Sitting on Plenty of CashIn its fourth quarter, SAGE lost $3.38 per share on revenue of just $0.28 million. But it ended the period with $922.8 million in cash, cash equivalents and marketable securities. This is up from $518.8 million at the end of 2017. Sage's management said it has enough cash on hand to fund expenses until the second half of next year (2020).Sage accelerated its R&D activity, which increased such expenses to $88.8 million, up from $50.9 million. IT spent $282.1 million in R&D for the full year 2018. Sage spent more on discovery efforts associated with identifying new clinical candidates, along with additional indications in its three CNS franchises. After the FDA approved Zulresso, R&D costs associated with Phase 3 clinical development may shift to marketing and G&A spend instead. Ahead of the launch, Sage spent $201.4 million in G&A costs, up sharply from $62.9 million last year. Sage's Full PipelineWithin Sage Therapetics' pipeline are more promising drugs. For example, SAGE-217 is being tested for efficacy in treating major depressive disorder, postpartum depression, biopolar depression and insomnia. Meanwhile, SAGE-324 has an indication for Parkinson's Disease, Essential Tremor and Epileptiform Disorders. The Bottom Line on Sage StockEven after Sage stock's recent rally, 10 analysts who follow the stock have an average12-month target price of $198 -- according to Tipranks. That's more than 25% upside. Biotech investors who are looking for similar stocks could consider Neurocrine Bio (NASDAQ:NBIX) or Zogenix (NASDAQ:ZGNX). * 5 Cloud Stocks to Help Your Portfolio Fly Sage Therapeutics has a promising drug that will not face any competition. Markets already expect strong sales for Zulresso. The company has a strong cash balance and plenty of more drugs in the pipeline. For these reasons, biotech investors should take a serious look at SAGE stock.Disclosure: As of this writing, the author did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Invincible Stocks Leading The Bull Market Higher * 5 Dow Jones Stocks Coming to Life * 7 of the Best High-Yield Funds for 2019 and Beyond Compare Brokers The post Sage Stock Pops on FDA Approval for Postpartum Depression Drug appeared first on InvestorPlace.

  • GlobeNewswire7 days ago

    Zogenix Enters Exclusive Distribution Agreement with Nippon Shinyaku for FINTEPLA® in Japan

    Zogenix, Inc. (ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it has entered into an exclusive distribution agreement with Nippon Shinyaku, Co., Ltd., a leading Japanese pharmaceutical product developer and distributor, for the commercialization of its lead product candidate, FINTEPLA® (ZX008, fenfluramine), in Japan. Zogenix is developing FINTEPLA internationally for the treatment of Dravet syndrome and Lennox-Gastaut syndrome (LGS), two rare and often catastrophic childhood-onset epileptic encephalopathies. Under the terms of the agreement, Nippon Shinyaku will receive exclusive commercial rights to FINTEPLA in Japan.

  • ACCESSWIRE20 days ago

    Non-Opioid Treatment Cos. for Investors in Wake of Purdue Pharma News

    HENDERSON, NV / ACCESSWIRE / March 6, 2019 / OxyContin maker Purdue Pharma is exploring filing for bankruptcy as one of its options to address potentially significant liabilities from thousands of lawsuits ...

  • GlobeNewswire20 days ago

    Research Report Identifies Zogenix, LivePerson, Valmont Industries, Carnival, Inphi, and Westlake Chemical Partners LP with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

    NEW YORK, March 06, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Thomson Reuters StreetEvents20 days ago

    Edited Transcript of ZGNX earnings conference call or presentation 28-Feb-19 9:30pm GMT

    Q4 2018 Zogenix Inc Earnings Call

  • Why Zogenix Shares Soared 20.5% in February
    Motley Fool21 days ago

    Why Zogenix Shares Soared 20.5% in February

    This company's epilepsy drug has been submitted for approval in the U.S. and Europe.

  • GlobeNewswire24 days ago

    Zogenix Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

    The awards were made on March 1, 2019 under Zogenix’s Employment Inducement Equity Incentive Award Plan, which provides for the granting of equity awards to new employees of Zogenix as an inducement to join the company.  The inducement awards consist of options to purchase an aggregate of 43,000 shares of Zogenix common stock.  The options have a ten-year term and an exercise price equal to $53.95, the fair market value of Zogenix common stock on the date of grant.  The options vest over a four-year period, with 25% of the options vesting on the first anniversary of each employee’s respective start date and the remainder vesting in equal monthly installments over the three years thereafter. The awards were approved by the independent compensation committee of Zogenix’s board of directors and were granted as an inducement material to the new employees entering into employment with Zogenix in accordance with Nasdaq Marketplace Rule 5635(c)(4).

  • Zogenix Inc (ZGNX) Q4 2018 Earnings Conference Call Transcript
    Motley Fool25 days ago

    Zogenix Inc (ZGNX) Q4 2018 Earnings Conference Call Transcript

    ZGNX earnings call for the period ending December 31, 2018.

  • GlobeNewswire25 days ago

    Zogenix Provides Corporate Update and Reports Fourth Quarter and Full-Year 2018 Financial Results

    Completed rolling submission of an NDA to the U.S. FDA and an MAA to the EMA for FINTEPLA® for the treatment of seizures associated with Dravet syndrome in February 2019-- EMA.

  • 3 Arguments For and Against Buying GW Pharmaceuticals
    Motley Fool27 days ago

    3 Arguments For and Against Buying GW Pharmaceuticals

    Does the leading cannabinoid-based drugmaker deserve a spot in your portfolio?

  • GlobeNewswirelast month

    Zogenix to Release Fourth Quarter and Full-Year 2018 Financial Results and Host Conference Call and Webcast on February 28

    EMERYVILLE, Calif., Feb. 21, 2019 -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it will report its.

  • GlobeNewswirelast month

    Zogenix to Present at the 8th Annual SVB Leerink Global Healthcare Conference

    EMERYVILLE, Calif., Feb. 20, 2019 -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that Stephen J. Farr,.

  • How an East Bay drug maker pivoted from opioids to the cusp of a seizure drug approval
    American City Business Journalslast month

    How an East Bay drug maker pivoted from opioids to the cusp of a seizure drug approval

    After the opioid crisis exploded and his company's painkiller was slammed by Massachusetts state officials, Zogenix Inc. CEO Stephen Farr knew the Emeryville drug developer needed to pivot — and fast. The company's done just that: It submitted applications last week to the Food and Drug Administration and the European Medicines Agency, asking the drug regulators to approve its drug, Fintepla, to treat seizures related to a rare form of epilepsy called Dravet syndrome. An answer from the FDA is expected later this year and from European regulators in early 2020.

  • GlobeNewswire2 months ago

    Zogenix Submits New Drug Application to U.S. Food & Drug Administration and Marketing Authorization Application to European Medicines Agency for FINTEPLA® for the Treatment of Dravet Syndrome

    Zogenix, Inc. (ZGNX), a global pharmaceutical company developing rare disease therapies, today announced it has completed its rolling submission of a New Drug Application (NDA) to the U.S. Food & Drug Administration (FDA) and submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for FINTEPLA (ZX008, low-dose fenfluramine) for the treatment of seizures associated with Dravet syndrome.

  • Are Insiders Selling Zogenix, Inc. (NASDAQ:ZGNX) Stock?
    Simply Wall St.2 months ago

    Are Insiders Selling Zogenix, Inc. (NASDAQ:ZGNX) Stock?

    Want to help shape the future of investing tools? Participate in a short research study and receive a subscription valued at $60. We often see insiders buying up shares in Read More...

  • GlobeNewswire2 months ago

    Detailed Research: Economic Perspectives on Advanced Micro Devices, Blackbaud, United States Cellular, CalAmp, Visteon, and Zogenix — What Drives Growth in Today's Competitive Landscape

    NEW YORK, Jan. 14, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of ZGNX earnings conference call or presentation 8-Nov-18 9:30pm GMT

    Q3 2018 Zogenix Inc Earnings Call

  • Is Zogenix, Inc.’s (NASDAQ:ZGNX) CEO Salary Justified?
    Simply Wall St.3 months ago

    Is Zogenix, Inc.’s (NASDAQ:ZGNX) CEO Salary Justified?

    Steve Farr has been the CEO of Zogenix, Inc. (NASDAQ:ZGNX) since 2015. This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar Read More...

  • JPMorgan Thinks This Pot Stock Is a "Clear Leader"
    Investopedia3 months ago

    JPMorgan Thinks This Pot Stock Is a "Clear Leader"

    The brokerage predicted that GW Pharmaceuticals’ cannabis-derived drug Epidiolex will eventually surpass $1 billion in annual sales.

  • Eversept Partners’ Return, AUM, and Holdings
    Insider Monkey3 months ago

    Eversept Partners’ Return, AUM, and Holdings

    Eversept Partners is a New York-based hedge fund that focuses on investing in companies from the healthcare sector. It was founded by its current portfolio manager Mr. Kamran Moghtaderi, who previously worked as an Analyst and Portfolio Manager at Apis Capital Advisors, LLC. Mr. Moghtaderi’s investment experience is much more extensive than this, as prior […]

  • GlobeNewswire3 months ago

    New Research: Key Drivers of Growth for Ashland Global, Intellia Therapeutics, Thor Industries, Zogenix, BWX Technologies, and Heidrick & Struggles International — Factors of Influence, Major Initiatives and Sustained Production

    NEW YORK, Dec. 17, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Here is What Hedge Funds Think About Zogenix, Inc. (ZGNX)
    Insider Monkey4 months ago

    Here is What Hedge Funds Think About Zogenix, Inc. (ZGNX)

    There are several ways to beat the market, and investing in small cap stocks has historically been one of them. We like to improve the odds of beating the market further by examining what famous hedge fund operators such as Carl Icahn and George Soros think. Those hedge fund operators make billions of dollars each […]